XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information
 6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Segment and Related Information SEGMENT AND RELATED INFORMATIONThe Company’s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.
Segment revenue and operating income (loss) were as follows during the periods presented:
(in millions)DiagnosticsOtherTotal
Three months ended June 30, 2021
Revenues$177.1 $12.3 $189.4 
Depreciation and amortization15.7 1.2 16.9 
Segment operating income (loss)37.5 (58.3)(20.8)
Three months ended June 30, 2020
Revenues$81.0 $12.2 $93.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(33.8)(34.5)(68.3)
Six months ended June 30, 2021
Revenues$334.9 $27.6 $362.5 
Depreciation and amortization32.7 2.6 35.3 
Segment operating income (loss)48.0 (115.5)(67.5)
Six months ended June 30, 2020
Revenues$231.5 $25.7 $257.2 
Depreciation and amortization33.5 2.1 35.6 
Segment operating loss(127.4)(74.6)(202.0)

Three months ended
June 30,		Six months ended
June 30,
(in millions)2021202020212020
Total operating loss for reportable segments$(20.8)$(68.3)$(67.5)$(202.0)
Unallocated amounts:
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Loss from operations before income taxes(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest— (0.1)— (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)